FluoGuide has submitted a Clinical Trial Application (CTA) to the Danish Medicines Agency to initiate phase II trial with FG001 in lung cancer

Copenhagen, Denmark, 22 December 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has submitted a CTA to initiate the phase II trial in lung cancer. The clinical trial will be conducted at Rigshospitalet in Denmark.

The release as fetched from its publisher. fluoguide.com ↗